INFORMATION DISCLOSURE STATEMENT CERTIFICATION

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

\bowtie	That each item of information contained in the inform	nation disclosure statement was first cited in		
any c	communication from a foreign patent office in a counterp	part foreign application not more than three		
month	nths prior to the filing of the information disclosure statem	ent. See 37 CFR 1.97(e)(1).		
OR				
	That no item of information contained in the information	tion disclosure statement was cited in a		
communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in				
the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(2).				
		spectfully submitted, odwin Procter LLP		
Dated	od: <u>October 21, 2009</u> By:	Ginger Dreger, Reg. No. 33,055		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Birgit Bossenmaier))
Application No.: 10/619,754) Group Art Unit: 1643
Filed: July 14, 2003) Examiner: Holleran, Anne)
For: Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies)))

PETITION TO CONSIDER INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

Sir:

Applicant hereby Petition the Commissioner to consider the references cited in the attached Information Disclosure Statement. The Information Disclosure Statement is being submitted after receipt of a Final Official Action or Notice of Allowance, but before payment of the issue fee, and is therefore accompanied by this Petition to Consider in accordance with the provisions of 37 C.F.R. 1.97(d). Also attached hereto is a Certification as required by this paragraph.

Please charge the Petition fee of \$130.00 under 37 CFR 1.17(i) to Deposit Account No. 50-4634 (Docket No. 123851-181770).

The Commissioner is authorized to charge any additional fees which may be required, including petition fees and extension of time fees, or credit any overpayment to Deposit Account No. 50-4634 (Docket No. 123851-181770). A duplicate copy of this paper is enclosed.

Respectfully submitted, GoodwinlProcter LLP

Date: October 21, 2009

By: Oigner Dreger Reg. No. 33.055

Goodwin|Procter LLP 135 Commonwealth Drive Menlo Park, CA 94025 Customer No. 77845

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application) PATENT APPLICAT	ION
Inventor(s): Built Bossenmaier, et al.)	
Application No. 10/619,754) Art Unit: 1643	
Filed: July 14,10 03) Examiner: Holleran, A	Anne
Title: Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodis)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along vi th a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicates respectfully request that the listed information be considered by the Examiner and be made of record in the heave-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and returnit in accordance with MPEP \$609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, α^* is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			
	(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR -			
		(2)	It is being filed within 3 months of entry of a national stage OR	
		(3)	It is being filed before the mail date of the first Office Action on the merits OR	
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.	
	37 C.F.R. §1,97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:			
		a certi	fication as specified in §1.97(e) is provided below; or	
			of \$180.00 as set forth in $\$1.17(p)$ is authorized below, enclosed, or included with the ent of other papers filed together with this statement.	
\boxtimes	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then			
	A.	a certi	fication as specified in §1.97(e) is completed below; and	
	B.		ion under 37 C.F.R. $\S1.97(d)$ requesting consideration of this statement is submitted ith; and	
	C.		of \$130.00 as set forth in $\$1.17(i)(1)$ is authorized below, enclosed, or included with the ent of other papers filed together with this statement.	
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$130.00 and charge any additional fees or credit any overpayment associated with this communicate to Deposit Account No. <u>50-4634 (Docket No. GNE-0114 (123851-181770)</u>).			
			Respectfully submitted, GOODWIN PROCTER LLP	
Dated:	Octobe	er 21, 20	09 By Ginger Dreger, Reg. No. 33,055	
Goodwin Procter LLP 135 Commonwealth Drive Menlo Park, CA 94025 (650) 752-3100 Customer No. 77845				